TCRT — Alaunos Therapeutics Income Statement
0.000.00%
- $6.76m
- $2.61m
- $0.01m
Annual income statement for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.398 | 2.92 | 0.005 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 57.9 | 80.4 | 77.9 | 38 | 34.3 |
Operating Profit | -57.9 | -80.4 | -77.5 | -35.1 | -34.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -118 | -80 | -78.8 | -37.7 | -35.1 |
Net Income After Taxes | -118 | -80 | -78.8 | -37.7 | -35.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -118 | -80 | -78.8 | -37.7 | -35.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -118 | -80 | -78.8 | -37.7 | -35.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -105 | -57.2 | -52 | -26.2 | -18.4 |